NZM Stock Chart & Stats
€53.50
-€2.00(-3.60%)
At close: 4:00 PM EDT
€53.50
-€2.00(-3.60%)
Day’s Range― - ―
52-Week Range€44.80 - €57.50
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€26.45B
Enterprise Value€30.82K
Total Cash (Recent Filing)€329.74M
Total Debt (Recent Filing)€3.22B
Price to Earnings (P/E)43.0
Beta0.43
Next Earnings
Aug 20, 2026EPS Estimate
0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.06
Shares Outstanding414,555,050
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.37
Price to Book (P/B)15.45
Price to Sales (P/S)40.34
P/FCF Ratio223.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.08
Revenue Forecast (FY)€4.44B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationTTM operating cash flow and free cash flow are robust and materially above net income, indicating durable cash conversion. That sustained cash generation supports capacity investments, integration of acquisitions, dividend/return choices and debt servicing, improving long-term financial flexibility.
High, Improving MarginsElevated gross and EBITDA margins—supported by pricing, product mix and early synergies—signal structural profitability. High margins enhance reinvestment capacity, buffer input cost swings and underpin sustained cash flow, making earnings more resilient across cycles and supporting long-term returns.
Diversified End Markets & InnovationBroad exposure (food, household, agriculture, industrial) plus ongoing product launches and scale-up capability create durable demand and high customer stickiness. Innovation and geographic penetration (incl. SE Asia/India) support sustainable volume growth and reduce dependence on any single market.
Bears Say
Historical VolatilityMaterial swings in annual revenue, margins and cash flow reduce predictability of medium-term earnings. This volatility complicates capacity planning, forecasting and capital allocation, raising execution risk for multi-year investments and making near-term durability of trends less certain.
Leverage Spike In 2025A notable increase in leverage in 2025 weakens balance-sheet optionality and could elevate refinancing risk if earnings soften. Even with low TTM debt metrics, episodic leverage increases constrain flexibility for opportunistic M&A or higher CapEx and raise sensitivity to cash-flow volatility.
CapEx & Opex Step-up PressureA planned near-term CapEx ramp and higher commercial opex increase cash demands and compress free cash flow until new capacity and commercial investments scale. Execution risk and timing of returns matter: if volume or synergies lag, margin and leverage targets could be harder to sustain.
Novonesis News
NZM FAQ
What was Novonesis’s price range in the past 12 months?
Novonesis lowest stock price was €44.80 and its highest was €57.50 in the past 12 months.
What is Novonesis’s market cap?
Novonesis’s market cap is €26.45B.
When is Novonesis’s upcoming earnings report date?
Novonesis’s upcoming earnings report date is Aug 20, 2026 which is in 3 days.
How were Novonesis’s earnings last quarter?
Novonesis released its earnings results on May 05, 2026. The company reported €0.434 earnings per share for the quarter, missing the consensus estimate of €0.708 by -€0.274.
Is Novonesis overvalued?
According to Wall Street analysts Novonesis’s price is currently Overvalued.
Does Novonesis pay dividends?
Novonesis does not currently pay dividends.
What is Novonesis’s EPS estimate?
Novonesis’s EPS estimate is 0.54.
How many shares outstanding does Novonesis have?
Novonesis has 414,555,050 shares outstanding.
What happened to Novonesis’s price movement after its last earnings report?
Novonesis reported an EPS of €0.434 in its last earnings report, missing expectations of €0.708. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Novonesis?
Currently, no hedge funds are holding shares in DE:NZM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novonesis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.93%
12-Months-Change
Fundamentals
Return on Equity
0.72%
Trailing 12-Months
Asset Growth
17.05%
Trailing 12-Months
Company Description
Novonesis
Novozymes A/S is a global biotechnology firm that specializes in the creation and distribution of industrial enzymes, microorganisms, and probiotics. Its operational footprint spans across Europe, the Middle East, Africa, North America, Latin America, and the Asia Pacific region. The company's broad range of products caters to numerous sectors: Food and Beverages: Supplying ingredients and processing aids for baking, a variety of beverages, dairy production, starch modification, and protein applications. Household Care: Delivering specialized formulations for laundry, dishwashing, and professional cleaning solutions. Agriculture: Providing innovations for crop cultivation, animal health and nutrition, alongside bioyield and biocontrol products for plant growth. Bioenergy and Industrial Processing: Offering critical components for grain and technical processing, encompassing liquefaction, saccharification, fermentation, fiber conversion, and biomass transformation. Textiles: Featuring technologies for biopreparation, biopolishing, bleach clean-up, denim abrasion and finishing, and desizing. Pulp and Paper: Enhancing processes through fiber modification, bleach boosting, deposit control, starch modification, and deinking agents. Leather Production: Furnishing treatments for acid bating, area expansion, general bating, degreasing, soaking, and unhairing/liming stages. Water and Waste Management: Contributing with bioaugmentation strategies, optimization of biogas production, and sludge management. Pharmaceuticals: Supplying specialized lipases (both free and immobilized), proteases for biocatalysis, and rTrypsin vital for cell culture applications. Furthermore, Novozymes provides offerings related to human health and various protein-based products. Founded in 1925, Novozymes A/S is headquartered in Bagsvaerd, Denmark.
NZM Company Deck
NZM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a positive operational and financial start to 2026: solid 7% organic growth, improved gross margin (+120 bps), strong cash flow and EPS (+8%), successful financing and ongoing integration synergies from the Feed Enzyme Alliance. Notable near-term headwinds include currency impacts, higher operating expenses and a temporary CapEx step-up, plus segment-specific softness in North American probiotics and timing-driven declines in tech/plant. Management maintains confident full-year guidance (5%–7% organic growth; 37%–38% adj. EBITDA margin) and reiterates medium-term targets, indicating that positives (growth, margins, cash, strategic M&A and product launches) materially outweigh the transitory negatives.View all DE:NZM earnings summariesNZM Revenue Breakdown
28.53% Household Care
24.83% Bioenergy
22.07% Food, Beverages & Human Health
12.82% Grain & Tech Processing
11.75% Agriculture & Animal Health

Technical Analysis
1 Day
3 Days
1 Week
1 Month
International Flavors & Fragrances
―
LyondellBasell
―
PPG Industries
―
RPM International
―
DuPont de Nemours
―










